Ringpu Bio-Technology gains approval for two new veterinary drugs

Ringpu Bio-Technology Co., Ltd., along with its subsidiaries, has obtained new veterinary drug registration certificates for two products. These include the "Porcine Circovirus Type 2, Mycoplasma Hyopneumoniae, and Haemophilus Parasuis Triplex Inactivated Vaccine" and the "African Swine Fever Virus ELISA Antibody Detection Kit." The vaccine, classified as a Class III new veterinary drug, received certificate number (2025) New Veterinary Drug Certificate No. 132.

The triplex inactivated vaccine, developed independently by Ringpu Bio-Technology, is a leading multi-valent vaccine for pigs in China. It targets the prevention of Porcine Circovirus Type 2 infection, Mycoplasma Hyopneumoniae, and Haemophilus Parasuis serotype 4 and 5 infections. The African Swine Fever Virus ELISA Antibody Detection Kit is designed to detect African Swine Fever virus antibodies in pig serum, providing crucial data for disease prevention and vaccine efficacy assessment.

These approvals signify Ringpu Bio-Technology's forward-looking strategy and innovation in the swine vaccine and animal disease diagnostic sectors. The company expects these products to enhance its market share and contribute to future business growth. Further applications for veterinary drug product approval numbers will be expedited.